Positive data from NAVIGATOR Phase III trial of tezepelumab in severe, uncontrolled asthma
In this RCT (n=1,061), tezepelumab, a first-in-class thymic stromal lymphopoietin inhibitor, added to standard of care (SoC) showed a 56% reduction vs. placebo plus SoC in annualised asthma exacerbation rate over 52 weeks.
Source:
Biospace Inc.
SPS commentary:
In this RCT (n=1,061), tezepelumab, a first-in-class thymic stromal lymphopoietin inhibitor, added to standard of care (SoC) showed a 56% reduction vs. placebo plus SoC in annualised asthma exacerbation rate over 52 weeks.